Revised SPC: Fabrazyme (agalsidase beta) 5 mg and 35 mg powder for concentrate for solution for infusion

SPC now advises initial infusion rate should be no more than 0.25mg/min (15mg/hour) to minimise potential occurrence of infusion-associated reactions and may be increased gradually with subsequent infusions after patient tolerance established.

Source:

electronic Medicines compendium